IBS, IBD, Crohn’s, and Ulcerative Colitis: A Short Review
Irritable bowel syndrome (IBS) functions as a functional gut disorder. It causes abdominal pain and alters bowel habits. Moreover, doctors do not see visible inflammation.
Inflammatory bowel disease (IBD) groups chronic conditions. It includes Crohn’s disease and ulcerative colitis, and both involve gut inflammation.
Crohn’s disease can affect any part of the gastrointestinal tract. Consequently, it often spreads deep into the bowel wall. It produces common symptoms such as pain, diarrhea, and weight loss.
Ulcerative colitis limits itself to the colon and rectum. Therefore, it causes continuous mucosal inflammation. It also leads to bloody stools and urgency.
Current Research Themes
- Microbiome studies
Gut bacteria differ in IBS, Crohn’s, and ulcerative colitis.
Researchers link dysbiosis to symptom severity.
- Genetic investigations
Multiple risk alleles have been identified for IBD.
Few strong links have emerged for IBS.
- Immune mechanisms
Crohn’s shows a Th1‑dominant response.
Ulcerative colitis shows a Th2‑dominant pattern.
IBS may involve low‑grade immune activation.
- Barrier function
Intestinal permeability is increased in IBD.
Some IBS patients also show a leaky gut.
- Dietary interventions
Low‑FODMAP diets help many IBS patients.
Exclusive enteral nutrition can induce remission in Crohn’s.
- Biologic therapies
Anti‑TNF agents are standard for Crohn’s and ulcerative colitis.
New anti‑integrin and anti‑IL‑12/23 drugs are under study.
- Microbiome‑targeted therapies
Fecal microbiota transplantation is being tested for IBS and IBD.
Engineered bacteria are being designed to deliver anti‑inflammatory molecules.
Key Findings
- Genome‑wide association studies have uncovered >200 IBD loci.
- Meta‑analyses show modest benefit of probiotics in ulcerative colitis.
- Brain‑gut axis research highlights stress as a trigger for IBS flares.
Future Directions
- Precision medicine aims to match therapy to genetic and microbial profiles.
- Single‑cell sequencing will map cellular changes in inflamed tissue.
- Novel drugs target gut‑specific pathways to reduce side effects.